|View printer-friendly version|
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005588/en/
“The recognition by
Labcorpwas the first company to receive an FDA Emergency Use Authorization to launch several COVID-19 PCR tests, including the Pixel by LabcorpⓇ COVID-19 PCR Test Home Collection Kit now available through retail, and helped bring multiple treatments and vaccines to market in record time. The company’s science and technology are also being leveraged to genetically sequence thousands of samples each week to identify variants that can inform future vaccines and treatments.
- Using robotics,
Labcorpincreased COVID-19 testing capacity and developed proprietary insight and analytics capabilities to help clients improve their operations, guide patient care, and support clinical trials across a larger number of programs and therapeutic areas.
- The company is improving the efficiency of clinical trials through the use of mobile and digital technologies to make decentralized and virtual clinical trials a reality.
Labcorpperformed over 40 million COVID-19 tests in the last year, more than any other U.S.commercial lab, and broadened access to COVID-19 testing for millions of people through hospitals, retail, employers, physicians, drive-through sites, and its Pixel by LabcorpCOVID-19 PCR Test Home Collection Kit.
The 2021 Most Innovative Companies list can be found on Fast Company’s website. Fast Company’s editors and writers sought out the most groundbreaking businesses around the globe in all industries. They also judged nominations received through their application process.
“In a year of unprecedented challenges, the companies on this list exhibit fearlessness, ingenuity and creativity in the face of crisis,” said Fast Company Deputy Editor
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to recognition and reputation of the Company. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the COVID-19 pandemic and its impact on our business and financial condition as well as general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, the effect of public opinion on the Company’s reputation, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, the number of revenue days in a financial period, personnel costs, and the effect of exchange rate fluctuations, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the